Cellectar Biosciences Inc. (NASDAQ:CLRB) went down by -1.54% during the previous trading session, and it is maintaining the win ahead of Tuesday’s trading session. The share price of the Biotechnology giant went up by $1.28 to trade ended Tuesday trading at $1.30. This is down from the $1.3 price recorded on Monday’s trading session. Thanks to this latest performance, CLRB is closer to the higher price 52-week target of $10.00 and further from the lowest price target of $3.00. Its performance from the start of the year has also been negative, with CLRB down by -43.11% year-to-date.
Cellectar Biosciences Inc. (CLRB) started the day trading at $1.29 and recorded an intraday high of $1.34. It also recorded an intraday low of $1.27 during Tuesday’s trading session. Cellectar Biosciences Inc. is a very active stock that recorded a trading volume that is less than -46.08% of the average daily trading volume on Tuesday. The stock’s trading volume on Tuesday was 448674, which is less than -46.08 of the total average daily trading volume of 655.43K.
Cellectar Biosciences Inc. (NASDAQ:CLRB) 2020 Performance Impressive
The increase in CLRB’s stock price on Tuesday saw its overall performance boost over the past few months. We can quantify the performance of the stock so far this year using a few metrics. The 52-week high price of CLRB currently stands at $3.33, which is higher than the current trading price of the stock by 61.56%. However, CLRB’s current trading price is -26.73% lower than the 52-week low price of $1.01. In terms of trading volume, Cellectar Biosciences Inc. currently experienced healthy participation during the last trading session. 448674 shares of Cellectar Biosciences Inc. were traded on the stock exchange on Tuesday, which is less than -46.08% of the 655.43K average trading volume of the stock.
The performance of the stock has been positive over the past year. CLRB’s performance over the past one year has seen it plunge by -39.91%, while the stock has gone down by -43.36% in the last six months. The quarterly performance of CLRB currently stands at -3.98%, and it is down by -10.49% in the last month. The only negative figure was from the weekly performance, which currently reads -0.78%. At the time of writing CLRB’s report, the company has a total market cap of $31.16M, making it one of the largest publicly-traded companies in the world.Cellectar Biosciences Inc. also has over 8 employees all over the world.
CLRB Insider Activities
For Cellectar Biosciences Inc., insiders hold 12.10% of all company shares. The insider transactions over the past six months are down by -245.00%. During that period, insiders bought 259,306 shares in 7 transactions. In that same period, insiders sold 0 of their shares in 0 transactions. After these transactions, insiders at Cellectar Biosciences Inc. now hold 242.23k shares, which is over 29.70% of the total company stocks. Institutional investors currently hold a large chunk of the CLRB shares, as they control 2.58% of the company’s total stock.
CLRB Fundamental Analysis
For Cellectar Biosciences Inc., the stock’s diluted earnings per share (EPS) stands at -1.66. In the coming year, analysts expect the EPS to be -1.30. The stock’s EPS growth this year is 64.90%, 59.80% in the previous five years. In terms of revenue, Cellectar Biosciences Inc.’s quarterly sales (YOY) is shrinking at -0.40, which is lower than the average annual revenue of 59.80% over the past half a decade.
CLRB Technical Analysis
The Simple Moving Average (SMA) is one of the most powerful technical indicators. The 20-day Simple Moving Average of CLRB currently stands at 5.05%, while the SMA50 is -8.58%. The biggest one is the SMA200, which is currently reading -29.56% ahead of Tuesday’s trading session. The Relative Strength Index of this stock is 47.63.